Realistic ambitions: Technology transfer for biologics platform technologies

Geoffrey Banda*, Cecilia Wanjala, Veronica Manduku, Dinar Kale

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract / Description of output

This chapter argues that the recent international support for expanding vaccine production in African countries offers local policymakers and industrialists an opportunity that should be seized, to transition local manufacturing capabilities to produce biologics. Biologics offer a broader portfolio of cancer therapies. Biologics such as monoclonal antibodies represent an incremental innovation for vaccine manufacturers, with lower learning and transition costs than those that would be faced by manufacturers of chemical drugs seeking to move into biologics. However, biologics production in Africa is not only a technological project, it is also political and economic, feeding into geo-politics debates.

Original languageEnglish
Title of host publicationCancer Care in Pandemic Times
Subtitle of host publicationBuilding Inclusive Local Health Security in Africa and India
EditorsGeoffrey Banda, Maureen Mackintosh, Mercy Karimi Njeru, Fortunata Songora Makene, Smita Srinivas
PublisherPalgrave Macmillan
Number of pages25
ISBN (Electronic)9783031441233
ISBN (Print)9783031441226, 9783031441257
Publication statusPublished - 11 Jan 2024

Publication series

NameInternational Political Economy Series
VolumePart F2092
ISSN (Print)2662-2483
ISSN (Electronic)2662-2491


Dive into the research topics of 'Realistic ambitions: Technology transfer for biologics platform technologies'. Together they form a unique fingerprint.

Cite this